Makino Haruhiko, Iraha Makiko, Manba Naoko, Hashidate Hideki, Shiotani Motoi
Division of Breast Surgery, Niigata City General Hospital, Japan.
Gan To Kagaku Ryoho. 2012 Feb;39(2):237-40.
Levels of serum human epidermal growth factor receptor-2 extracellular domain(HER2ECD )were measured in breast cancer patients. Fifty-six patients had advanced or recurrent disease, and 21 others were preoperation patients who received neoadjuvant therapy. In the tissue HER2-positive group of advanced or recurrent patients, levels of serum HER2ECD at first recurrence were high(≥15. 3 ng/mL)in 75%of patients, and significantly higher(p=0. 03)than in the tissue HER2-negative group. In neoadjuvant therapy patients, the levels of serum HER2ECD were high in 50% of the tissue HER2-positive group, and within the normal limit in all the tissue HER2-negative group(p=0. 015). The levels of serum HER2ECD were closely correlated with treatment efficacies in both recurrent and neoadjuvant patients. In this study, the levels of serum HER2 ECD appeared to be useful for diagnosis of recurrence in HER2-positive breast cancer and for estimation of therapy in recurrent and neoadjuvant patients as a secondary bio-marker.
对乳腺癌患者血清人表皮生长因子受体2胞外域（HER2ECD）水平进行了检测。56例患者患有晚期或复发性疾病，另外21例为接受新辅助治疗的术前患者。在晚期或复发性患者的组织HER2阳性组中，75%的患者首次复发时血清HER2ECD水平较高（≥15.3 ng/mL），且显著高于组织HER2阴性组（p = 0.03）。在新辅助治疗患者中，组织HER2阳性组50%的患者血清HER2ECD水平较高，而组织HER2阴性组所有患者的血清HER2ECD水平均在正常范围内（p = 0.015）。血清HER2ECD水平与复发患者和新辅助治疗患者的治疗效果密切相关。在本研究中，血清HER2ECD水平似乎可作为一种次要生物标志物，用于HER2阳性乳腺癌复发的诊断以及复发和新辅助治疗患者的治疗评估。
